NCT05753878View on ClinicalTrials.gov

A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions
COVID-19
Interventions
DRUG

HH-120 nasal spray, PartA cohort 1

A single dose of HH-120 nasal spray premixed with 1mg/ml methylene blue injection.

DRUG

HH-120 nasal spray, Part A cohort 2-7

A single dose of HH-120 nasal spray.

DRUG

HH-120 nasal spray, Part A cohort 8-9

Two doses of HH-120 nasal spray.

DRUG

HH-120 nasal spray, Part B

HH-120 nasal spray, 10 times daily for 7 consecutive days.

OTHER

Placebo nasal spray, Part B

Placebo nasal spray, 10 times daily for 7 consecutive days.

Trial Locations (1)

100730

Beijing TongRen Hospital, Capital Medical University, Beijing

Sponsors

Lead Sponsor

Huahui Health
All Listed Sponsors
lead

Huahui Health

INDUSTRY

NCT05753878 - A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers | Biotech Hunter | Biotech Hunter